Streptococcus pneumoniae pep27 mutant as a live vaccine for serotype-independent protection in mice

Vaccine

Volumn 30, Issue 11, 2012, Pages 2008-2019

  Kim, Eun Hye ^a   Choi, Sang Yoon ^a   Kwon, Min Kyoung ^a   Tran, Thao Dang Hien ^a   Park, Sang Sang ^a   Lee, Kwang Jun ^c   Bae, Song Mee ^c   Briles, David E ^a,b   Rhee, Dong Kwon ^a  

^a Sungkyunkwan University   (South Korea)

^b Korea Centers for Disease Control and Prevention   (South Korea)

^c University of Alabama at Birmingham   (United States)

Author keywords

Cross protection; Immunity; Live vaccine; Pep27 mutant; Streptococcus pneumoniae

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; AUTOLYSIS; BACTEREMIA; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM MUTANT; BLOOD; COLONY FORMING UNIT; IMMUNIZATION; LUNG; MALE; MOUSE; NONHUMAN; NOSE INFECTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VIRULENCE; WILD TYPE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; IMMUNOGLOBULIN G; MALE; MICE; MUTATION; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, ATTENUATED; VIRULENCE;

EID: 84862776504     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.073     Document Type: Article

References (62)

1. Willett H.P. Streptococcus pneumoniae. Zinsser microbiology 1992, 432-442. Prentice-Hall International, London, United Kingdom. W.K. Joklik, H.P. Willet, D.B. Amos, C.M. Wilfert (Eds.).
2. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., Dowell S.F., File T.M., Musher D.M., Niederman M.S., Torres A., Whitney C.G. Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society concensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
3. Gray B.M., Converse G.M., Dillon H.C. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life. J Infect Dis 1980, 142(6):923-933.
4. I.H. Park, D.G. Pritchard, R. Cartee, A. Brandao, M.C. Brandileone, M.H. Nahm Discovery of a New Capsular Serotype (6C) within Serogroup 6 of Streptococcus.
5. Bogaert D., Hermans P.W., Adrian P.V., Rümke H.C., de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004, 22(17-18):2209-2220.
6. Isaacman D.J., McIntosh E.D., Reinert R.R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010, 14(3):197-209.
7. Oosterhuis-Kafeja F., Beutels P., Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007, 25(12):2194-2212.
8. Poolman J.T. Pneumococcal vaccine development. Expert Rev Vaccines 2004, 3(5):597-604.
9. Gladstone R.A., Jefferies J.M., Faust S.N., Clarke S.C. Continued control of pneumococcal disease in the UK - the impact of vaccination. J Med Microbiol 2011, 60(Pt 1):1-8.
10. McEllistrem M.C., Adams J., Mason E.O., Wald E.R. Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine. J Infect Dis 2003, 188(11):1679-1684.
11. Käyhty H., Auranen K., Nohynek H., Dagan R., Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev Vaccines 2006, 5(5):651-667.
12. Oliveira M.L., Arêas A.P., Ho P.L. Intranasal vaccines for protection against respiratory and systemic bacterial infections. Expert Rev Vaccines 2007, 6(3):419-429.
13. Jambo K.C., Sepako E., Heyderman R.S., Gordon S.B. Potential role for mucosally active vaccines against pneumococcal pneumonia. Trends Microbiol 2010, 18(2):81-89.
14. Ogunniyi A.D., Folland R.L., Briles D.E., Hollingshead S.K., Paton J.C. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 2000, 68(5):3028-3033.
15. Wu H.Y., Nahm M.H., Guo Y., Russell M.W., Briles D.E. Intranasal immunization of mice with PspA (pneumococcal surface protein A) can prevent intranasal carriage, pulmonary infection, and sepsis with Streptococcus pneumoniae. J Infect Dis 1997, 175(4):839-846.
16. Yamamoto M., McDaniel L.S., Kawabata K., Briles D.E., Jackson R.J., McGhee J.R., Kiyono H. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect Immun 1997, 65(2):640-644.
17. Xin W., Wanda S.Y., Li Y., Wang S., Mo H., Curtiss R. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis. Infect Immun 2008, 76(7):3241-3254.
18. Briles D.E., Ades E., Paton J.C., Sampson J.S., Carlone G.M., Huebner R.C., Virolainen A., Swiatlo E., Hollingshead S.K. Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae. Infect Immun 2000, 68(2):796-800.
19. Jakobsen H., Saeland E., Gizurarson S., Schulz D., Jónsdóttir I. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections. Infect Immun 1999, 67(11):4128-4133.
20. Sabirov A., Metzger D.W. Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue. Vaccine 2008, 26(12):1566-1576.
21. Shah P., Briles D.E., King J., Hale Y., Swiatlo E. Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae. Exp Biol Med 2009, 234(4):403-409.
22. Lu Y.J., Forte S., Thompson C.M., Anderson P.W., Malley R. Protection against pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 2009, 77(5):2076-2083.
23. Roche A.M., King S.J., Weiser J.N. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun 2007, 75(5):2469-2475.
24. Roche A.M., Weiser J.N. Identification of the target of cross-reactive antibodies induced by Streptococcus pneumoniae colonization. Infect Immun 2010, 78(5):2231-2239.
25. Avery O.T., Macleod C.M., McCarty M. Studies on the chemical nature of the substance inducing transformation of pneumococcal types. Induction of transformation by a desoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med 1944, 79(2):137-158.
26. Vasseghi H., Claverys J.P. Amplification of a chimeric plasmid carrying an erythromycin-resistance determinant introduced into the genome of Streptococcus pneumoniae. Gene 1983, 21(3):285-292.
27. Håvarstein L.S., Coomaraswamy G., Morrison D.A. An unmodified heptadecapeptide pheromone induces competence for genetic transformation in Streptococcus pneumoniae. Proc Natl Acad Sci U S A 1995, 92(24):11140-11144.
28. Bricker A.L., Camilli A. Transformation of a type 4 encapsulated strain of Streptococcus pneumoniae. FEMS Microbiol Lett 1999, 172(2):131-135.
29. Schmeck B., Gross R., N'Guessan P.D., Hocke A.C., Hammerschmidt S., Mitchell T.J., Rosseau S., Suttorp N., Hippenstiel S. Streptococcus pneumoniae-induced caspase 6-dependent apoptosis in lung epithelium. Infect Immun 2004, 72(9):4940-4947.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65(1-2):55-63.
31. Lee I.J., Kim K.W., Hyun J.W., Lee Y.H., Park E.W. Comparative ultrastructure of nonwounded Mexican lime and Yuzu leaves infected with the citrus canker bacterium Xanthomonas citri pv.citri. Microsc Res Tech 2009, 72(2):507-516.
32. Kwon H.Y., Ogunniyi A.D., Choi M.H., Pyo S.N., Rhee D.K., Paton J.C. The ClpP protease of Streptococcus pneumoniae modulates virulence gene expression and protects against fatal pneumococcal challenge. Infect Immun 2004, 72(10):5646-5653.
33. Austrian R. The quelling reaction, a neglected microbiologic technique. Mt Sinai J Med 1976, 43(6):699-709.
34. Haas W., Sublett J., Kaushal D., Tuomanen E.I. Revising the role of the pneumococcal vex-vncRS locus in vancomycin tolerance. J Bacteriol 2004, 186(24):8463-8471.
35. Novak R., Charpentier E., Braun J.S., Tuomanen E. Signal transduction by a death signal peptide: uncovering the mechanism of bacterial killing by penicillin. Mol Cell 2000, 5(1):49-57.
36. Novak R., Henriques B., Charpentier E., Normark S., Toumanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999, 399(6736):590-593.
37. Robertson G.T., Zhao J., Desai B.V., Coleman W.H., Nicas T.I., Gilmour R., Grinius L., Morrison D.A., Winkler M.E. Vancomycin tolerance induced by erythromycin but not by loss of vncRS, vex3, or pep27 function in Streptococcus pneumoniae. J Bacteriol 2002, 184(24):6987-7000.
38. Lee M.S., Dougherty B.A., Madeo A.C., Morrison D.A. Construction and analysis of a library for random insertional mutagenesis in Streptococcus pneumoniae: use for recovery of mutants defective in genetic transformation and for identification of essential genes. Appl Environ Microbiol 1999, 65(5):1883-1890.
39. Saunders C.W., Guild W.R., Properties transforming activities of two plasmids in Streptococcus pneumoniae. Mol Gen Genet 1980, 180(3):573-578.
40. Tran T.D., Kwon H.Y., Kim E.H., Kim K.W., Briles D.E., Pyo S., Rhee D.K. Decrease in penicillin susceptibility due to heat shock protein ClpL in Streptococcus pneumoniae. Antimicrob Agents Chemother 2011, 55(6):2714-2728.
41. Malley R., Henneke P., Morse S.C., Cieslewicz M.J., Lipsitch M., Thompson C.M., Kurt-Jones E., Paton J.C., Wessels M.R., Golenbock D.T. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 2003, 100(4):1966-1971.
42. Seo H.S., Michalek S.M., Nahm M.H. Lipoteichoic acid is important in innate immune responses to gram-positive bacteria. Infect Immun 2008, 76(1):206-213.
43. Berry A.M., Lock R.A., Hansman D., Paton J.C. Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect Immun 1989, 57(8):2324-2330.
44. Tuomanen E., Pollack H., Parkinson A., Davidson M., Facklam R., Rich R., Zak O. Microbiological and clinical significance of a new property of defective lysis in clinical strains of pneumococci. J Infect Dis 1988, 158(1):36-43.
45. Lysenko E.S., Ratner A.J., Nelson A.L., Weiser J.N. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog 2005, 1(1):e1.
46. Johnsborg O., Håvarstein L.S. Regulation of natural genetic transformation and acquisition of transforming DNA in Streptococcus pneumoniae. FEMS Microbiol Rev 2009, 33(3):627-642.
47. Burton R.L., Nahm M.H. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006, 13(9):1004-1009.
48. World Health Organization. Pneumococcal vaccines [position paper]. Wkly Epidemiol Rec 74;1999:177-83.
49. Tyrrell G.J., Lovgren M., Chui N., Minion J., Garg S., Kellner J.D., Marrie T.J. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 2009, 27(27):3553-3560.
50. Malley R., Lipsitch M., Stack A., Saladino R., Fleisher G., Pelton S., Thompson C., Briles D., Anderson P. Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci. Infect Immun 2001, 69(8):4870-4873.
51. Wu H.Y., Virolainen A., Mathews B., King J., Russell M.W., Briles D.E. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog 1997, 23(3):127-137.
52. Martner A., Skovbjerg S., Paton J.C., Wold A.E. Streptococcus pneumoniae autolysis prevents phagocytosis and production of phagocyte-activating cytokines. Infect Immun 2009, 77(9):3826-3837.
53. Magee A.D., Yother J. Requirement for capsule in colonization by Streptococcus pneumoniae. Infect Immun 2001, 69(6):3755-3761.
54. Talbot U.M., Paton A.W., Paton J.C. Uptake of Streptococcus pneumoniae by respiratory epithelial cells. Infect Immun 1996, 64(9):3772-3777.
55. Nelson A.L., Roche A.M., Gould J.M., Chim K., Ratner A.J., Weiser J.N. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun 2007, 75(1):83-90.
56. Zhang Z., Clarke T.B., Weiser J.N. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009, 119(7):1899-1909.
57. Fabrizio K., Manix C., Tian H., van Rooijen N., Pirofski L.A. The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. Vaccine 2010, 28(47):7542-7550.
58. Dockrell D.H., Marriott H.M., Prince L.R., Ridger V.C., Ince R.G., Hellewell P.G., Whyte M.K. Alveolar macrophage apoptosis contributes to pneumococcal clearance in a resolving model of pulmonary infection. J Immunol 2003, 171(10):5380-5388.
59. Marriott H.M., Dockrell D.H. The role of the macrophage in lung disease mediated by bacteria. Exp Lung Res 2007, 33(10):493-505.
60. Marriott H.M., Hellewell P.G., Cross S.S., Ince P.G., Whyte M.K., Dockrell D.H. Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia. J Immunol 2006, 177(9):6480-6488.
61. Ali F., Lee M.E., Iannelli F., Pozzi G., Mitchell T.J., Read R.C., Dockrell D.H. Streptococcus pneumoniae-associated human macrophage apoptosis after bacterial internalization via complement and Fc gamma receptors correlates with intracellular bacterial load. J Infect Dis 2003, 188(8):1119-1131.
62. Molloy A., Laochumroonvorapong P., Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin. J Exp Med 1994, 180(4):1499-1509.